Open Access

OBM Transplantation

LIDSEN Publishing Inc.

Review

Allogeneic Stem Cell Transplantation: Current Status and Future Directions

Ajay Kumar [1, *], Juveriya Israr [2]

1. Department of Biotechnology, Faculty of Engineering and Technology, Rama University, Mandhana, Kanpur, Uttar Pradesh 209217, India; E-Mail: ajaymtech@gmail.com; ORCID: 0000-0003-3654-5566
2. Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Lucknow-Deva Road, Barabanki, Uttar Pradesh 225003, India; E-Mail: juveriyaisrar2016@gmail.com

* **Correspondence:** Ajay Kumar; E-Mail: ajaymtech@gmail.com; ORCID: 0000-0003-3654-5566

Academic Editor: Haval Shirwan

OBM Transplantation
2025, volume 9, issue 1
doi:10.21926/obm.transplant.2501241

Received: August 03, 2024
Accepted: March 02, 2025
Published: March 12, 2025

Abstract

Allogeneic stem cell transplantation (allo-SCT) improves the treatment of hematopoietic cancer and non-malignant disease. In this case, stem cells from a genetically similar but not identical donor may stimulate immune-mediated tumor cell destruction. Allogeneic stem cell transplantation, or allo-SCT, has significantly extended the life expectancy of numerous people. Nevertheless, complications such as infections, graft-versus-host disease (GVHD), and recurrence continue. This paper provides a thorough analysis of the possibility of allo-SCT. Advancements in allo-SCT have recently enhanced outcomes and diminished the adverse effects and mortality associated with treatment. The number of potential donors for allogeneic stem cell transplantation has grown due to the utilization of haploidentical and umbilical cord blood transplantation. One strategy to improve overall survival and decrease the occurrence of GVHD is to use T-cell depletion in conjunction with cyclophosphamide administration following transplantation. The goal of studying allo-SCT is to increase the graft-versus-tumor effects with few side effects. To enhance the body's natural mechanisms for combating tumors, researchers are investigating checkpoint inhibitors and CAR T-cell therapy. Manipulating genes and using precision medicine techniques could improve the process of

selecting donors and decrease the occurrence of GVHD. This study proposes that allo-SCT could benefit non-malignant conditions such as autoimmune and metabolic disorders. The therapeutic efficacy may be enhanced by combining allo-SCT with innovative targeted and immunomodulatory medications. allo-SCT is being enhanced to enhance safety and expand its applicability to other diseases. Recent advances may improve patient outcomes and establish allo-SCT as a successful hematological and related treatment.

Keywords
Allogeneic stem cell transplantation; hematopoietic stem cell transplantation; graft-versus-host disease; donor selection; patient selection; complications and management

1. Introduction

A medical procedure known as allo-stem cell transplantation (allo-SCT) involves transferring stem cells from a donor with distinct genetic traits to a recipient to replace unhealthy or damaged cells with donor-derived ones. The donor can be a relative or an unrelated person. A vital therapeutic choice for various blood-related cancers, genetic abnormalities, and autoimmune diseases, this treatment helps restore the recipient's immunological and hematopoietic systems [1].

Haematologic cancers, genetic disorders, and autoimmune diseases are among the many ailments that allo-SCT is vitally necessary to cure. When faced with a potentially fatal illness, allo-SCT is an excellent therapy option. It may one day supply a fresh supply of immune system-repairing stem cells that may differentiate into various cell types [2]. allo-SCT has made significant progress since its inception in the 1950s, evolving into a curative treatment for several oncological, genetic, and immunological illnesses. The voyage commenced with the initial human investigations, which established the groundwork for comprehending the intricacies of hematopoietic stem cell transplantation (HSCT). Scientists have made tremendous progress over time in addressing the adverse health consequences and mortality rates associated with transplants, as well as enhancing the eradication of malignant diseases through the graft-versus-leukemia (GvL) effect [3]. HSCT emerged as a viable therapeutic option throughout the 1950s. Initial investigations predominantly centered on using bone marrow as a storage site for stem cells. A major medical breakthrough occurred in the 1960s when doctors were able to treat patients with severe combined immunodeficiency illnesses with allogeneic hematopoietic stem cell transplant (HCT) treatments. Severalleukemia patients in the 1970s underwent allogeneic HCTs. Bone marrow transplants necessitated the use of unrelated donors. Everything went smoothly during the HCT procedures. HSCT conditioning regimens that were either less intense or did not cause myeloablative reactions were more common in the 1980s. Because of this, people with preexisting conditions or who are very old might get the surgery. In recognition of his groundbreaking work promoting HCT as a very effective treatment for serious blood diseases, E. Donnall Thomas was bestowed the Nobel Prize in Medicine/Physiology in the 1990s. More stem cell expansion options became available in the 2000s when granulocyte-colony stimulating-mobilized peripheral and cord blood stem cells were more widely available. At now, allo-SCT is used as a therapy for blood cancers such as leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Current research is focused on

improving outcomes and reducing complications, namely GVHD. The advancement of allo-SCT processes and protocols has undergone a gradual and significant process, marked by noteworthy advancements throughout the years.

In regenerative medicine, stem cells are vital because they allow injured tissues and organs to heal and regenerate. Their versatility as stem cells, the capacity to develop into numerous cell types, and secretion of healing factors make them helpful in treating various ailments [4-6].

Initially, the primary objective was to understand the fundamental principles of HSCT and validate the efficacy of using stem cells from non-patient donors. The initial accomplishments involved successfully performing allogeneic HCT procedures on individuals with severe combination immunodeficiency diseases and leukemia. The achievements mentioned provided the basis for subsequent progress in this field [3]. Older adults and those with co-occurring medical issues were formerly ineligible for HSCT, but this changed in the 1980s and 1990s when less intense conditioning regimens were used. This improvement made the treatment more feasible and safer. The pool of potential donors has grown thanks to creating donor categories such as haploidentical donors, matched related donors, mismatched related donors, matched unrelated donors, and umbilical cord blood donors. Consequently, there has been a notable enhancement in the success rates of transplants and a rise in the number of available donors. The graft-versus-tumor (GVT) effect is the specific elimination of cancer cells by white blood cells derived from a donor. Acquiring an understanding of this occurrence has been crucial in improving the effectiveness of allo-SCT for eliminating malignant disorders such as leukemia and lymphomas. GVHD are serious complications of allogeneic transplantation; reducing their risk requires Human leukocyte antigens (HLA) matching [7]. Using less intense conditioning regimens, such as fludarabine and melphalan, has demonstrated the potential to reduce mortality caused by treatment, enhance overall survival rates, and decrease the incidence of GVHD, particularly in individuals diagnosed with acute myeloid leukemia. Recent studies have focused on evaluating the cost-effectiveness of allo-SCT.

Research suggests that employing reduced-intensity conditioning in some populations of patients could offer a more cost-effective and practical treatment strategy for conditions that include acute myeloid leukemia (AML). More generally, allogeneic stem cell transplantation techniques have progressed and protocols have involved a progressive improvement in conditioning regimens, criteria for selecting donors, and modifications to protocols. The objective of these modifications is to enhance the efficacy of transplants, reduce the occurrence of problems, and broaden the application of this life-preserving technique. Ongoing research and advancements are consistently impacting the field of allo-SCT, offering hope for improved patient outcomes and expanded treatment options in the realm of blood and lymphatic tumors.

2. Transplantation of Stem Cells from a Donor

Stem cells used in allo-SCT come from a source other than the patient. Donated stem cells can originate from anyone, related or not, to the recipient. Before initiating an allo-SCT, the patient gets a preliminary treatment called conditioning, which entails the injection of either chemotherapy or radiation. Some individuals undergo concurrent administration of both medications. Conditioning treatment is employed to eradicate any residual cancer cells within the body. To make sure the patient accepts the donor cells lowers their immune system. Conditioning treatment promotes the movement of recently developed cells via the bloodstream to the recipient's bone marrow. The

transplanted cells in the bone marrow facilitate the generation of several blood constituents, such as erythrocytes, leukocytes, and thrombocytes. This process is referred to as "engraftment". An allo-SCT can directly eliminate cancer cells in certain types of blood cancers. The occurrence is denoted as the GVT effect, and it happens when donor immune cells attack tumors recognize the cancerous cells within the recipient's body as foreign, and initiate a battle against them. GVT is essential for the effectiveness of treatment in some patients. It can help prevent the recurrence of cancer. This benefit is only available with allo-SCT. Autologous stem cell transplants do not involve it. Many blood malignancies, such as leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, are treated using allo-SCT (Figure 1) [8].



Figure 1 The image depicts the procedure of allogeneic stem cell transplantation. After the stem cells are obtained from the donor, they are combined with a cryoprotective agent to facilitate freezing for long-term storage. When a suitable patient is discovered and requires the cells, they can be safely thawed and transported to the patient.

3. Allogeneic Transplantation Tissue Typing

As soon as the doctor thinks allogeneic stem cell transplantation could help the patient, they will start looking for a donor who is a good match. An ideal match is crucial for most patients as it increases the likelihood of a successful transplant by aiding the integration of the donor stem cells. As a result, the patient's body can generate new blood cells, which reduces the chances of complications.

3.1 HLA Matching

Human leukocyte antigens (HLAs) are unique proteins or markers that are present on the surface of the majority of human cells. They consist of an individual's tissue type, distinct to each individual. The patient and potential donor undergo blood testing to determine if their HLA profiles are compatible. There are numerous HLA indications. Because individuals inherit half of their HLA markers from their mother and the other half from their father, a patient's sibling, who shares the same HLA markers, is usually the most suitable candidate to serve as a donor. On average, a person's sibling has a one in four chance of having the same HLA type. However, it is essential to note that many individuals do not have siblings with the same tissue type [9].

3.2 Transplanting Mismatched, Unrelated Donors

To minimize the risk of graft-versus-host disease, your doctor will strive to match 10 to 12 HLA markers. Because of recent medical advancements, mismatched stem cell donors in which not all 10 or 12 markers match ideally- can now be used. Medications can be employed to utilize donors who are not a perfect match, hence reducing the likelihood of graft-versus-host disease [10].

3.3 Haploidentical Transplantation

For patients unable to identify a precisely matched HLA donor, several transplant facilities are now performing half-match (haploidentical) transplants to increase the pool of possible donors. A parent, sibling, or other healthy first-degree relative can frequently give stem cells and be a half-match donor. A biological kid and their parent will always be a half match because a child gets half of their HLA markers from their parent, but there is only a 50% probability that a sibling will be a half match. Most people will therefore have a suitable related haploidentical donor [11-13].

3.4 Cord Blood Transplantation

Blood extracted from a newborn baby's umbilical cord is called cord blood. Patients who don't have a compatible donor may be able to get cord blood. Regretfully, cord blood units may be challenging for individuals with more significant body proportions due to their relatively lower stem cell content. Patients who get cord blood transplants are more likely to experience graft failure. In contrast, cord blood can be acquired far faster, perhaps within two to four weeks, than matched unrelated donor grafts, which could need up to a month to procure. One additional benefit of cord blood transplantation is the possibility of reduced HLA matching requirements between the donor and receiver [14, 15].

4. Current Status of Allogeneic Stem Cell Transplantation

A variety of blood malignancies and non-cancerous disorders can still be effectively treated with allo-SCT. Advancements in transplant procedures, donor selection, and supportive care have greatly enhanced outcomes for allo-SCT patients. Research has shown that allo-SCT can cure diseases like acute myeloid leukemia, myelodysplastic syndromes, and lymphomas, with encouraging long-term survival rates. Gratwohl et al. conducted a study that revealed that patients who had allo-SCT for acute myeloid leukemia had a 65% survival rate after 5 years [16]. Progress in reduced-intensity

conditioning regimens has also expanded the pool of patients who can undergo transplantation to include older adults and those with co-occurring medical conditions. This has improved the availability and effectiveness of allo-SCT [17]. Despite obstacles such as GVHD and infections, current research is focused on enhancing transplant results, customizing treatment methods, and investigating innovative tactics to improve the effectiveness and safety of allo-SCT further. Table 1 shows current and future perspectives on Allogeneic Stem Cell Transplantation.

Table 1 Current and Future Perspectives on Allogeneic Stem Cell Transplantation.

S. No.	Aspect	Current Status	Future Directions	References
1	Therapeutic Role	Curative approach for various blood cancers (leukemia, lymphoma) and non-malignant conditions (aplastic anemia)	Potential for broader application in autoimmune diseases and metabolic disorders	[18-20]
2	Donor Selection	Preference for HLA-matched sibling donors	Increased use of alternative donor sources (haploidentical, unrelated)	[18-20]
3	Conditioning Regimens	Chemotherapy and/or radiation to suppress the recipient's immune system	Development of reduced-intensity conditioning for broader patient eligibility	[18-20]
4	Graft-versus-Host Disease (GVHD) Prophylaxis	Immunosuppressive medications to prevent GVHD	Novel GVHD prophylaxis strategies with reduced toxicity	[18-20]
5	Incorporation of Targeted Therapies	Integration of targeted therapies with allo-HSCT for improved outcomes	Identifying optimal timing and combinations	[18-20]
6	Measurable Residual Disease (MRD)-Directed Therapy	Post-transplant therapy based on minimal residual disease detection	Personalized treatment strategies based on MRD status	[18-20]
7	Reducing Relapse and Non-Relapse Mortality	Major challenge limiting long-term survival	Development of new strategies to prevent relapse and improve supportive care	[18-20]

Several hematological cancers can be effectively treated by allogeneic hematopoietic cell transplantation, often known as allo-HCT. However, problems including treatment-related mortality (TRM), graft-versus-host disease (GVHD), and underlying illness recurrence greatly affect patient

outcomes. Effective risk management in allo-HCT requires an understanding of the relationship between these elements (Bishop and Keating) [21].

5. Graft-Versus-Host Disease (GVHD)

A serious consequence that can develop after an allogeneic stem cell or bone marrow transplant is GVHD, in which the immune cells from the donor assault the tissues of the recipient. Inflammation and organ damage are hallmarks of this illness, caused mainly by the transplanted cells' immune reaction mistaking the host body for a foreign invader [22]. There are primarily two categories of GVHD.

5.1 Acute GVHD

5.1.1 When

You might see it later, although it usually happens within the first hundred days after a transplant.

5.1.2 Organs Affected

Disrupts the skin, liver, and gastrointestinal (GI) system mainly.

5.1.3 Symptoms

Maculopapular rash (often mistaken for a sunburn), jaundice (a result of liver involvement), and gastrointestinal issues (diarrhoea, stomach pain, etc.) are common signs. Between 30 and 70 percent of transplant recipients may experience acute GVHD.

5.2 Chronic GVHD

5.2.1 Time

Chronic GVHD typically manifests more than 100 days after transplantation, though it can happen at any point.

5.2.2 Organs

It impacts various organs, including the skin, liver, GI tract, connective tissues, and exocrine glands.

5.2.3 Symptoms

Some symptoms include thickened skin, dry eyes and mouth, stiff joints, and systemic issues that resemble autoimmune diseases. About 40% to 50% of patients who undergo allogeneic transplants may develop chronic GVHD.

5.3 Pathophysiology

In GVHD, donor-derived T lymphocytes mistake the recipient's tissues for foreign ones because of variations in HLA markers. The host's tissues are inflamed and damaged due to this immunological reaction. Donor and recipient HLA matching, age, and the amount of conditioning before transplantation are some factors that can determine the severity of GVHD.

5.4 Diagnosis

Genomic venous hemorrhage diagnosis is based on clinical symptoms, with additional confirmation from lab work and, if needed, biopsies. Here are some critical signs to look out for.

Lesions or rashes on the skin, Liver injury indicated by elevated bilirubin or liver enzyme values and Severe diarrhea or stomach pain are signs of gastrointestinal distress.

5.5 Treatment

The management of GVHD focuses on immunosuppression to mitigate the immune response. Treatment strategies typically include.

5.5.1 Corticosteroids

Prednisone or methylprednisolone are commonly used to reduce inflammation and immune activity.

5.5.2 Additional Immunosuppressive Agents

Other medications may be employed depending on the severity of symptoms. The prognosis for patients with GVHD varies based on the severity of the condition and the organs involved. While many cases can be managed successfully, severe cases may lead to significant complications, including infections due to immunosuppression. In summary, GVHD is a complex condition that requires careful monitoring and management following stem cell transplantation to ensure patient safety and improve outcomes [23, 24].

6. Relapse

Many hematological malignancies, including AML and myelodysplastic syndromes (MDS), have a high risk of recurrence following allo-HSCT. Improving patient outcomes requires a deeper understanding of relapse, including its occurrence, processes, and implications.

6.1 Incidence of Relapse

6.1.1 General Rates

Depending on the patient's characteristics and the kind of disease, the recurrence rate following allo-HSCT can be anywhere from 10% to 30%. One study found that 10-30% of myelofibrosis patients have recurrence after transplantation [25].

6.1.2 Specific Conditions

One of the leading causes of death in AML is relapse after transplantation. There is a greater risk of central nervous system (CNS) relapse in patients with acute lymphoblastic leukemia (ALL) after allo-HSCT for AML, with a reported incidence of approximately 1.81% [26].

6.2 Mechanisms of Relapse

The capacity of leukemic cells to elude the immune surveillance initially set up by the donor's immune system is a common cause of relapse. Multiple processes cause this to happen.

6.2.1 Immune Escape

One way leukemic cells can evade the immune system is by lowering the expression of the HLA. Despite previous immune control, the malignancy can proliferate because of this downregulation, which hinders T-cell identification [27, 28].

6.2.2 Mutational Persistence

Relapse can occur in MDS if the disease-causing hematopoietic stem cells remain after a transplant. Evidence from mutational screening suggests that relapse risk forecasts can be improved by recognizing residual disease [29].

6.3 Graft-Versus-Leukemia Effect

The graft-versus-leukemia impact can be amplified by GVHD, although severe GVHD can also increase treatment-related mortality. Relapse rates were shown to be lower in patients with moderate GVHD, while non-relapse mortality rates were found to be considerably higher [25].

6.4 Prognosis and Outcomes

After a relapse, the outlook is usually not good. For instance, at three years, just 18% of AML patients have survived following a CNS relapse. To identify and treat minimal residual disease (MRD) early, it is necessary to create reliable monitoring methods [26].

6.5 Treatment Strategies

Various therapy techniques are often utilized in the management of recurrence following allo-HSCT.

6.5.1 Cellular Immunotherapy

If the disease returns, treatment options include second allo-HSCT and donor lymphocyte infusion (DLI). Restoring immunological control over the leukemic cells is the goal of these therapies [28].

6.5.2 Targeted Therapies

Checkpoint inhibitors, which may improve T-cell responses against recurrent leukemia, are one example of a newer therapy modality undergoing investigation [27]. To sum up, hematological malignancies face the formidable obstacle of recurrence following allo-HSCT. The goal of ongoing research is to improve patient treatment and outcomes after transplantation by understanding the underlying mechanisms and developing better diagnostic tools.

7. Transplant-Related Mortality (TRM)

Patients undergoing HSCT, especially allo-HSCT, are at high risk of transplant-related mortality (TRM). TRM is defined as fatalities caused by transplant-related complications rather than the underlying disease. Better patient management and results can be achieved by increasing our understanding of TRM, including its occurrence, causes, and contributing variables.

7.1 Incidence of TRM

7.1.1 Overall Rates

Transplant type and patient characteristics are two of the many variables that affect the TRM rate. Research has shown that in the initial few years following a transplant, the rate of TRM for allo-HSCT can range from 18% to 32%. For instance, across all transplants, one study discovered a 1-year TRM rate of 18.3%; among allo-HSCT patients, the cumulative incidence over 5 years was 24.1% [30, 31].

7.1.2 Comparison with Autologous HSCT

The TRM rate following autologous HSCT (auto-HSCT) is typically lower, at about 7% during three years. This disparity emphasizes the dangers of allo-HSCT, which include immunosuppression and graft-versus-host disease (GVHD) [31].

7.2 Causes of TRM

The main factors that contribute to TRM are complex and include.

7.2.1 Infections

Close to one-third to one-half of all instances of TRM are infections. Because of their immunosuppression and persistent neutropenia, patients having allo-HSCT are at a higher risk [30].

7.2.2 Graft-Versus-Host Disease (GVHD)

About 34% of TRM cases are caused by GVHD, making it another substantial contributor. Damage to numerous organs caused by severe acute or chronic GVHD can result in significant morbidity and death [32].

7.2.3 Other Complications

Conditions such as veno-occlusive disease (VOD), graft failure, and organ toxicity caused by conditioning regimens are other potential reasons. The reasons could differ depending on the donor type and the patient's preexisting condition.

7.3 Risk Factors for Increased TRM

Patients having allo-HSCT are at increased risk of TRM for a variety of reasons.

7.3.1 Donor Type

Compared to transplants from unrelated or mismatched donors, the TRM rate is typically lower in matched sibling transplants. For example, compared to other types of donors, matched sibling donors had a substantially decreased cumulative incidence of TRM at 100 days post-transplant [30].

7.3.2 Patient Age and Comorbidities

Higher rates of problems leading to TRM are associated with older age and pre-existing health issues.

7.3.3 Disease Status at Transplantation

Relapse and treatment-related nausea and vomiting may occur more frequently in patients with advanced disease or who have received previous therapies. Patients' chances of survival and overall well-being are greatly affected by TRM, which is still a significant obstacle in allo-HSCT. Continued research is focused on finding ways to reduce TRM by enhancing donor selection, conditioning protocols, and supportive care measures. Optimizing transplant results and improving patient safety during this complex treatment process requires clinicians to understand the multifaceted nature of TRM.

8. Gene Therapy and CART Therapy Role in Allogenic Stem Cell Transplantation

Innovative techniques to treat various hematological malignancies and genetic abnormalities are being offered by gene therapy and CAR T-cell therapy (CART treatment), which are regarded as significant developments in the context of allo-HSCT [33].

In gene therapy, a patient's cells are modified or new genetic material is introduced to fix or replace disease-causing faulty genes. For patients without acceptable HLA-matched donors, gene therapy can be an alternative to allo-HSCT. Gene therapy reduces the dangers of allo-HSCT, including GVHD and transplant-related death, by utilizing autologous HSCs. The viability of using CRISPR/Cas9 and other *ex vivo* gene editing tools to fix genetic mutations in HSCs before reinfusion into the patient has been proven by recent advances. This method eliminates the risks connected with donor-derived cells while simultaneously improving the possibility of long-term therapeutic effects by addressing the underlying genetic abnormalities [34].

In contrast, chimeric antigen receptor (CAR) T-cell therapy modifies a patient's T cells to target cancer cells specifically. Relapsed or refractory B-cell malignancies have been remarkably treated with this medication. By combining CAR T-cell treatment with allo-HSCT, the graft-versus-tumor

effect- the process by which donor immune cells target any remaining cancer cells following transplantation- can be amplified. A potential improvement in results could be achieved by combining CAR T-cell treatment with allo-HSCT. This approach uses both the immune response from donor cells and the specific action of modified T cells.

Regarding stem cell transplantation, gene therapy, and CAR T-cell treatment are giant leaps forward in customized medicine, providing options that could lessen risks and increase the effectiveness in treating complicated disorders. These medicines can potentially revolutionize treatment for patients undergoing allo-HSCT as research advances [34].

9. Specific Advantages of Allogeneic Stem Cell Transplantation

There are a number of benefits to allo-HSCT compared to auto-HSCT and other forms of stem cell transplantation. The main advantages are as follows.

9.1 Immune Response Against Cancer

The graft-versus-tumor (GVT) effect, in which immune cells from the donor target any remaining cancer cells in the recipient's body, is one of the most notable advantages of allo-HSCT. Hematological tumors, such as lymphoma and leukemia [35, 36], are especially susceptible to this immune-mediated response, which may improve results in the fight against cancer. On the other hand, the use of the patient's immune system in auto-HSCT prevents this effect from occurring.

9.2 Graft Free of Cancer

Allogeneic grafts are sourced from healthy donors, guaranteeing that they do not contain any cancerous cells, reducing cancer risk. Because reintroducing malignant cells by auto-HSCT is a real possibility, this is very helpful for cancer patients.

9.3 Available Donor Sources

The allo-HSCT procedure offers a number of donor options for stem cell transplantation. These include peripheral blood, bone marrow, and umbilical cord blood. Patients without enough healthy stem cells for an autologous transplant have a better chance of finding a compatible donor in this larger pool.

9.4 Possibility of Commercial Use

It is possible to prepare and store allogeneic therapies in advance, so they can be used immediately if necessary. Urgent medical situations, where time is of the essence, are ideal for this "off-the-shelf" type. Increasing the Number of Eligible Patients

9.5 Appropriate for Patients at High Risk

When other therapy options have been exhausted or the patient has a high-risk condition, allo-HSCT is frequently the best choice. Patients who cannot undergo auto-HSCT due to a lack of healthy stem cells or other medical conditions now have a chance.

9.6 Rates Over the Long Term

In some patient groups, especially those with aggressive or recurrent malignancies, allo-HSCT may result in higher percentages of long-term survival than auto-HSCT, according to research. This benefit is a result of both the GVT effects and the capacity to transplant healthy donor cells into hematopoietic systems that are malfunctioning. To summarize, allogeneic stem cell transplantation has several benefits over autologous transplantation. These include a better chance of a successful immune response against malignancies, access to grafts that are clear of cancer, and a wider range of patients who are eligible, even those at high risk of complications. These characteristics enhance treatment results for solid tumors and hematological malignancies [37].

10. Advancements and Emerging Technologies and Techniques in Allogeneic Stem Cell Transplantation

Allo-SCT has made significant progress by introducing new conditioning regimens, enhancing donor selection procedures, implementing targeted medicines for GVHD prophylaxis, and adopting reduced-intensity conditioning protocols. Novel conditioning regimens, such as lymph depletion techniques utilizing monoclonal antibodies or pharmacologic agents, have been created to improve the success of engraftment and decrease the likelihood of recurrence among patients who have received a transplant of donor stem cells [7]. Enhanced methods for selecting donors, such as utilizing alternative donors like haploidentical or cord blood donors, have broadened the range of transplant choices available for patients lacking a compatible donor, resulting in greater access to transplants and better overall results. GVHD prevention can be improved using targeted medicines, such as immune checkpoint inhibitors or biological drugs targeting immune pathways. These therapies provide more accurate and efficient management of GVHD while reducing the harmful side effects of treatment [38]. To further lessen the impact of these adverse side effects, strategies for reduced-intensity conditioning have been established and mortality rates linked to therapy in elderly or medically compromised individuals. This allows a broader range of patients to have allo-SCT, including individuals from various populations [39]. The advancement of new technology and techniques has greatly enhanced the success rates of organ transplants and broadened the range of applications for stem cell therapy. Gene editing has significantly improved transplant outcomes by enabling precise alterations to the donor cells before transplantation. This encompasses the utilization of genetically modified T cells, which can be programmed to selectively attack particular cancer cells and enhance the graft-versus-tumor response [40]. The expansion of stem cells outside the body, known as ex vivo expansion, has become an essential element in stem cell therapy. This entails the augmentation of the quantity of stem cells outside the organism before transplantation, which might enhance the likelihood of successful integration and diminish the probability of graft failure. In addition, CAR-T cell treatment has effectively been utilized in allogeneic transplantation, wherein genetically engineered T cells are engineered to attack cancer cells and deliver potent immunotherapy selectively. The progress made in this field has dramatically enhanced the effectiveness and security of stem cell transplantation, providing fresh optimism for individuals suffering from various illnesses.

11. Risk Management of Allogeneic Transplantation, Challenges and Limitations

To maximize patient outcomes and minimize procedure-related problems, risk management is crucial in allogeneic transplantation. Potential organ donors are carefully chosen based on several criteria, including age, illness stage, and general health. Transplant recipients and donors must have highly similar HLA markers to lessen significantly the likelihood of GVHD, a prevalent and dangerous consequence in which the donor's immune cells assault the recipient's tissues. For donor stem cells to be successfully engrafted into a recipient's body, the patient must first undergo a conditioning treatment that may involve radiation or chemotherapy to eradicate any lingering cancer cells. In the weeks immediately following a transplant, when white blood cell counts are at an all-time low, patients must be closely monitored for infections. Antibiotics and antiviral drugs are used as preventative treatments to lessen the likelihood of infection. The effective prevention or treatment of GVHD also includes administering immunosuppressive medications as part of its management. Late consequences, such as chronic GVHD, organ dysfunction, and possible return of the underlying disease, must be monitored by continuous follow-up care. This will ensure that patients receive therapies when they are needed. Improving the efficacy and safety of allogeneic transplantation requires a multidisciplinary strategy that incorporates education, support, and proactive management methods.

allo-SCT can save lives for patients suffering from many forms of blood cancer. Nevertheless, it encounters several obstacles, such as GVHD, Relapse, Transplant Mortality (TRM), Infections, and Optimal Engraftment. allo-SCT faces significant obstacles such as graft failure, delayed engraftment, and insufficient immune reconstitution. Delayed Engraftment might result in an extended period of low levels of neutrophils and platelets, which raises the likelihood of developing infections and experiencing bleeding problems. Insufficient immune reconstitution can also heighten the susceptibility to infections and recurrence. Long-term complications and survivability difficulties encompass the delayed consequences of conditioning regimens, the start of GVHD at a later stage, and the potential for acquiring subsequent malignancies. Utilizing allo-SCT significantly impacts a patient's quality of life, underscoring the significance of ongoing research and advancements to improve patient outcomes and long-term survival [41-43].

12. Future Directions in Allogeneic Stem Cell Transplantation

allo-SCT has made substantial breakthroughs in recent years, although there are still areas that require more progress to enhance patient outcomes. Important future areas of focus include personalized medicine strategies, such as genomic profiling, the integration of immunotherapy, breakthroughs in studies involving stem cells, and scientists studying and cultivating stem cells *in vitro* (*ex vivo*). Genomic profiling enables the identification of patients who have a greater likelihood of benefiting from allo-SCT and those who are at a higher risk of experiencing problems. This information allows for the development of personalized treatment regimens. The incorporation of immunotherapy can augment the graft-versus-tumor effect and promote patient outcomes, encompassing the utilization of CAR-T cell treatment and other immunotherapeutic drugs. Advancements in stem cell research can result in higher rates of successful transplantation, decreased occurrence of GVDH, and improved restoration of the immune system. Adoptive immunotherapy, a technique involving T cells from a donor to specifically attack cancer cells, can be incorporated into transplant procedures to strengthen the immune response against the tumor.

Utilizing immune reconstitution techniques, such as administering cytokines and growth factors, can enhance patient outcomes by mitigating the likelihood of infections and recurrence. Expanding stem cells outside of the body can enhance the success of transplanting them, decrease the possibility of the transplanted cells failing, and improve the rebuilding of the immune system. A novel and trustworthy source of stem cells, induced pluripotent stem cells (iPSCs) make stem cell transplantation a breeze. The goal of stem cell engineering is to increase the therapeutic potential of stem cells by manipulating them. This is achieved by utilizing gene editing technologies to fix genetic abnormalities and boost the overall function of the stem cells [3, 44].

13. Clinical Trials and Research Initiatives

The Dana-Farber Cancer Institute is a renowned establishment that researches allogeneic hematopoietic stem cell/bone marrow transplantation (HSCT). Their research primarily focuses on developing novel medicines to prevent or treat GVHD, a frequently occurring side effect of allogeneic HSCT. Their scientists have made significant and innovative findings about the involvement of B cells and interleukin-2 in the management of GVHD. They are actively researching these and other new treatments. In addition, they engage in the creation of novel immunotherapy and vaccine approaches aimed at enhancing the therapeutic graft-versus-tumor response and managing the recurrence of the disease. In addition, they tackle issues arising from the compromised immune system of individuals receiving stem cell transplantation. Results from a meta-analysis of 24 clinical trials show that allogeneic stem cell transplantation (allo-SCT) does not improve overall survival rates for patients with acute myeloid leukemia (AML) in the first complete remission stage compared to other non-allogeneic treatment options. Across all cytogenetic risk categories, this result remains consistent. The precise function of allo-SCT (allogeneic stem cell transplantation) in AML (acute myeloid leukemia) during the first complete remission (CR1), particularly in various cytogenetic risk categories, requires more investigation [45, 46].

14. Ethical Dilemmas in Stem Cell Transplantation

allo-SCT entails administering medicines to healthy donors, which raises ethical considerations for professionals participating in the procedure. The process of commercializing and patenting stem cells, as well as their isolation procedure, pose a threat to human integrity and dignity, as they can be used by external entities and may not conform to universally accepted or specific notions of human dignity. Insufficient assessment of new technology might result in ethical dilemmas, such as the dissemination of fabricated data, and hinder the recruitment of patients for subsequent clinical trials. Survivor bias is a common problem in data on health-related quality of life after stem cell transplantation, with little consideration given to those who are in the process of dying. The potential for therapy-induced mortality raises questions regarding the dignity of patients who may be compelled to endure high-risk medicines that may have a negative impact rather than a positive one. The consent procedure for stem cell transplantation requires the involvement of patients, family members, and healthcare professionals to make informed decisions and respect the patient's autonomy. This is especially important when the patient is a minor. Establishing guidelines for fertility preservation during stem cell transplantation is crucial for effectively addressing medical concerns and enabling patients to make well-informed choices regarding their reproductive well-being. Choosing a donor gives rise to ethical considerations regarding the rights of children and

teenagers and the importance of valuing their input in decisions regarding their well-being. Integrating palliative care into stem cell transplantation presents a moral quandary for healthcare practitioners, as they must strike a balance between providing life-saving treatment and preserving the dignity of terminally ill patients [47, 48].

15. Prevention and Treatment of GVHD

15.1 The Standard Prophylactic Regimens for the Prevention and Treatment of GVHD

15.1.1 Inhibitors of Calcineurin

Since the 1980s, the gold standard for GVHD prevention has been methotrexate plus tacrolimus or cyclosporine. These drugs lessen the likelihood of GVHD by lowering T-cell activation and proliferation [49].

15.1.2 Regimens Based on Cyclophosphamide

According to recent research, a three-drug regimen that includes cyclophosphamide, tacrolimus, and mycophenolate mofetil yields better results than the conventional two-drug regimen. This method improved GVHD-free survival rates and drastically decreased GVHD incidence in trials, all without raising relapse or infection rates [50].

15.2 New Treatments

Acute GVHD can be prevented with monoclonal antibodies, such as the recently approved abatacept. As an alternative to conventional prophylaxis, abatacept blocks T-cell activation. Efforts are being made to develop therapies targeting immune cells, particularly to optimize GVHD prevention. One example is the use of chemo-cytokine antagonists and mesenchymal stem cells. Another is the depletion of T cells [49].

15.3 Ways to Eliminate T Cells

Reducing the likelihood of GVHD while maintaining some graft-versus-leukemia effects is possible with techniques that remove T cells from donor grafts. Mismatched donor transplants are one area where this technique shines [50].

16. Disease Relapse Management and Monitoring Disease with Minimal Remaining (MRD)

Relapse after transplant can be prevented with early intervention strategies made possible by enhanced MRD monitoring. If we want better results in the long run, we need to take this proactive approach. The graft-versus-tumor effect: It is crucial to balance preventing GVHD and taking advantage of this beneficial effect. Researchers are looking to lower recurrence rates after allo-HSCT by increasing beneficial T-cell responses and decreasing harmful ones.

17. Methods for Dealing with Serious Infections - *Antivirals and Antibiotics for Prevention*

To avoid infections caused by immunosuppression, taking prophylactic antibiotics, antifungals, and antivirals during the neutropenic phase following a transplant is crucial. Current studies are focused on creating individualized plans for preventing infections by analyzing microbiomes and patient risk factors. The utilization of monoclonal antibodies against specific pathogens and advanced antimicrobial therapies are among the new therapeutic options being investigated as a means to improve infection management in immunocompromised patients during their recovery from allo-HSCT. To summarize, to enhance the results for patients having allogeneic stem cell transplants, there has to be progress in preventing and treating GVHD, managing disease relapse, and ways to deal with severe infections. Personalized medicine and innovative therapies are the centers of current research efforts to improve these approaches and increase treatment efficacy and patient safety [51].

18. Conclusion

Haematologic cancers and other non-cancerous disorders may be amenable to allogeneic stem cell transplantation. It offers the potential to eliminate the disease and achieve long-term remission. Although the operation has the potential to cure, it is not without hazards, including graft-versus-host disease, infections, and organ toxicities. However, its safety and applicability have been greatly improved by advances in conditioning regimens, donor selection, and supportive care. Continuing research is currently dedicated to enhancing results and minimizing difficulties; allogeneic stem cell transplantation remains a crucial therapy choice, highlighting its vital role in transforming the field of hematological disorders.

Abbreviations

ALL	Acute lymphoblastic leukemia
AML	Acute myeloid leukemia
allo-SCT	Allogeneic stem cell transplantation
CNS	Central nervous system
DLI	Donor lymphocyte infusion
CR1	First complete remission
GI	Gastrointestinal
GVHD	Graft-versus-host disease
GVL	Graft-versus-leukemia
GVT	Graft-versus-tumor
HCT	Hematopoietic stem cell transplant
HSCT	Hematopoietic stem cell transplantation
HLAs	Human leukocyte antigens
iPSCs	Induced pluripotent stem cells
MDS	Myelodysplastic syndromes
TRM	Transplant Mortality
TRM	Treatment-related mortality

Author Contributions

JI and AK developed the outline of this article; JI, AK wrote the original draft, which was edited by AK. All authors agreed to the final version to be submitted.

Competing Interests

The authors have declared that no competing interests exist.

References

1. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, et al. Bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies: A systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014; 140: 2027-2035.
2. Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: More than 40,000 transplants annually. Bone Marrow Transplant. 2016; 51: 786-792.
3. Singh AK, McGuirk JP. Allogeneic stem cell transplantation: A historical and scientific overview. Cancer Res. 2016; 76: 6445-6451.
4. Fathi E, Farahzadi R, Sheervalilou R, Sanaat Z, Vietor I. A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy. Blood Res. 2020; 55: 10-16.
5. Fathi E, Valipour B, Vietor I, Farahzadi R. An overview of the myocardial regeneration potential of cardiac c-Kit$^+$ progenitor cells via PI3K and MAPK signaling pathways. Future Cardiol. 2020; 16: 199-209.
6. Farahzadi R, Valipour B, Montazersaheb S, Fathi E. Targeting the stem cell niche micro-environment as therapeutic strategies in aging. Front Cell Dev Biol. 2023; 11: 1162136.
7. Koreth J, Matsuoka Ki, Kim HT, McDonough SM, Bindra B, Alyea III EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011; 365: 2055-2066.
8. Vo CD, Myhre AE, Abrahamsen IW, Remberger M, Mattsson J, Fløisand Y, et al. Allogeneic stem cell transplantation in adults 2015-21. Tidsskr Nor Laegeforen. 2023; 143. doi: 10.4045/tidsskr.22.0521.
9. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol. 2004; 11: 386-391.
10. Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, et al. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014; 20: 1485-1492.
11. Vittayawacharin P, Kongtim P, Ciurea SO. Future directions in haploidentical hematopoietic stem cell transplantation. Hematology. 2024; 29: 2366718.
12. Arcuri LJ, Ribeiro AAF, Hamerschlak N, Kerbauy MN. Posttransplant cyclophosphamide beyond haploidentical transplantation. Ann Hematol. 2024; 103: 1483-1491.
13. Henslee-Downey PJ. Haploidentical transplantation. Cancer Treat Res. 1999; 101: 53-77.
14. Cohen Y, Nagler A. Cord blood biology and transplantation. Isr Med Assoc J. 2004; 6: 39-46.

15. Wagner JE. Allogeneic umbilical cord blood transplantation. Cancer Treat Res. 1997; 77: 187-216.
16. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: A retrospective observational study. Lancet Haematol. 2015; 2: e91-e100.
17. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, et al. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Ann Hematol. 2017; 96: 289-297.
18. Ma R, Liu XT, Chang YJ. Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: Current status and future directions mainly focusing on a Chinese perspective. Expert Rev Hematol. 2022; 15: 789-803.
19. O'Reilly RJ. Allogeneic bone marrow transplantation: Current status and future directions. Blood. 1983; 62: 941-964.
20. Powles R. 50 years of allogeneic bone-marrow transplantation. Lancet Oncol. 2010; 11: 305-306.
21. Bishop MR, Keating A. Hematopoietic stem cell transplantation. In: Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020. pp. 1159-1164.e2.
22. Im A, Pavletic SZ. Hematopoietic stem cell transplantation. In: Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020. pp. 461-469.e463.
23. Reddy P, Ferrara JL. Graft-versus-host disease and graft-versus-leukemia responses. In: Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018. pp. 1650-1668.e1610.
24. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis. 2007; 2: 35.
25. Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024; 59: 550-557.
26. Blum S, Chalandon Y, Labopin M, Finke J, Gedde-Dahl T, Othman TB, et al. Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2024; 109: 2346.
27. Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood J Am Soc Hematol. 2019; 133: 1290-1297.
28. Sauerer T, Velázquez GF, Schmid C. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: Immune escape mechanisms and current implications for therapy. Mol Cancer. 2023; 22: 180.
29. Rodriguez-Sevilla JJ, Colla S. A road map of relapse in MDS after allo-HSCT. Blood. 2024; 143: 941-943.
30. Hazar V, Karasu G, Uygun V, Akcan M, Küpesiz A, Yeşilipek A. Hematopoietic stem cell transplantation activity and trends at a pediatric transplantation center in Turkey during 1998-2008. Turk J Haematol. 2012; 29: 143-149.
31. Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: A systematic review and meta-analysis. JAMA Netw Open. 2021; 4: e219807.

32. Chiesa R, Boelens JJ, Duncan CN, Kühl J-S, Sevin C, Kapoor N, et al. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. Blood Adv. 2022; 6: 1512-1524.
33. Staal FJ, Aiuti A, Cavazzana M. Autologous stem-cell-based gene therapy for inherited disorders: State of the art and perspectives. Front Pediatr. 2019; 7: 443.
34. Lawal RA, Walters MC, Fitzhugh CD. Allogeneic transplant and gene therapy: Evolving toward a cure. Hematol Oncol Clin North Am. 2022; 36: 1313-1335.
35. Giralt S, Bishop MR. Principles and overview of allogeneic hematopoietic stem cell transplantation. Cancer Treat Res. 2009; 44: 1-21.
36. Karadurmus N, Sahin U, Basgoz BB, Arpaci F, Demirer T. A review of allogeneic hematopoietic stem cell transplantation in metastatic breast cancer. Int J Hematol Oncol Stem Cell Res. 2018; 12: 111-116.
37. Erwin H. Medical advantages of allogeneic vs autologous stem cell transplants as treatment in blood related cancer patients [Internet]. Fairfield, CT: Sacred Heart University; 2018. Available from: https://digitalcommons.sacredheart.edu/acadfest/2018/all/131/.
38. Zeiser R, Blazar BR. Acute graft-versus-host disease-biologic process, prevention, and therapy. N Engl J Med. 2017; 377: 2167-2179.
39. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: A review. Springer Semin Immun. 2004; 26: 71-94.
40. Marcuzzi A, Maximova N. Advances in stem cell therapy: New applications and innovative therapeutic approaches. Front Med. 2023; 10: 1225551.
41. Lee SE, Lee JW. Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia. Blood Cell Ther. 2018; 1: 9-17.
42. Malagola M, Greco R, Peccatori J, Isidori A, Romee R, Mohty M, et al. Strengths and challenges of allo-SCT in the modern era. Front Oncol. 2022; 12: 850403.
43. McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med. 2015; 7: 280rv282.
44. Atilla E. Hematopoietic stem cell transplantation: Back to the future. Front Med. 2024; 11: 1390041.
45. Trounson A, McDonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell. 2015; 17: 11-22.
46. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301: 2349-2361.
47. Droste S, Herrmann-Frank A, Scheibler F, Krones T. Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: A systematic literature review. BMC Med Ethics. 2011; 12: 6.
48. Liso A, Neri M, Maglietta F, La Russa R, Turillazzi E. Hematopoietic stem cell transplantation: A bioethical lens. Stem Cells Int. 2017; 2017: 1286246.
49. Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014; 11: 536-547.
50. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in

complete remission—A review from the Acute Leukemia Working Party of the EBMT. Haematologica. 2015; 100: 859-869.

51. Niederwieser C, Iacobelli S, Franke GN, Koster L, van Os M, Platzbecker U, et al. Reduced intensity versus myeloablative conditioning for MDS: Long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant. 2024; 59: 1084-1091.